Pulmonary venous thrombosis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:23:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pulmonary venous thrombosis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Rosuvastatin for Reducing Blood Clots in Patients with Deep Vein Thrombosis or Pulmonary Embolism https://clinicaltrials.eu/trial/study-on-rosuvastatin-for-reducing-blood-clots-in-patients-with-deep-vein-thrombosis-or-pulmonary-embolism/ Wed, 29 Apr 2026 14:30:35 +0000 https://clinicaltrials.eu/trial/study-on-rosuvastatin-for-reducing-blood-clots-in-patients-with-deep-vein-thrombosis-or-pulmonary-embolism/ This clinical trial is focused on studying the effects of a medication called Rosuvastatin Calcium in patients who have experienced certain types of blood clots. The diseases being studied include Pulmonary Embolism, Venous Thromboembolism, and Deep Vein Thrombosis. These conditions involve the formation of blood clots in the veins, which can be serious and require medical attention. The trial will compare the effects of Rosuvastatin Calcium to a placebo, which is a substance with no active medication, to see if the medication can help reduce the occurrence of these blood clots.

The purpose of the study is to determine if taking Rosuvastatin Calcium can lower the rate of major blood clot events in patients who have already had a clot. Participants in the study will be randomly assigned to receive either Rosuvastatin Calcium or a placebo. The study will monitor the participants over a period of time to observe any differences in the recurrence of blood clots between the two groups. The trial will also look at other health outcomes, such as the development of post-thrombotic syndrome, which is a condition that can occur after a blood clot, and other vascular events like heart attacks or strokes.

Throughout the study, participants will be regularly checked to ensure their safety and to gather information on how the medication is affecting their health. The trial is expected to continue until the end of 2027, providing valuable insights into the potential benefits of Rosuvastatin Calcium for patients with these types of blood clots.

]]>